By using our website, you agree to the use of our cookies.


Fund performance

Important information: Past performance is no guarantee of future returns. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back the entire invested capital. As at: Oct 29, 2021.

Rhenman Healthcare Equity L/S (RHE L/S)
June 2024
The fund performance is calculated and reported once a month.
IC1 (EUR)988.882.06%13.50%888.88%2009-06-22
IC3 (EUR)1267.302.11%14.84%1167.30%2009-07-31
IC2 (SEK)809.421.50%14.94%709.42%2012-12-31
ID1 (SEK)Distributing464.311.46%10.08%364.31%2012-04-30
IC1 (USD)240.880.75%11.87%140.88%2015-01-31
IC2 (USD)332.920.79%11.85%232.92%2014-04-30
RC1 (EUR)843.402.01%13.46%743.40%2010-08-31
RC1 (SEK)935.741.42%14.51%835.74%2009-06-22
RC2 (SEK)998.701.46%14.71%898.70%2009-06-22



Historical returns are not a guarantee of future returns. The money you invest in can both increase and decrease in value and you may not get back all the invested capital. Rhenman Healthcare Equity L/S is an AIF which is only available to retail investors in Sweden and Finland, and it is registered for professional investors only in Belgium, Netherlands, Italy, United Kingdom, Singapore (restricted scheme offered to accredited investors only), Switzerland (distributed without FINMA registration).

Focus on healthcare

Rhenman Healthcare Equity L/S (RHE L/S) is a multiple award-winning hedge fund that focuses on the healthcare sector. The fund invests globally in companies within pharmaceuticals, biotechnology, medical technology and services and has a flexible investment mandate.

RHE L/S aims to generate an average annual net return of at least 12% over time, regardless of the stock market’s performance. It is a long-biased fund but actively adjusts risk based on the managers’ perception of opportunities and market risks. The fund can go long as well as sell shares short.

Sector with great potential

For many decades, the healthcare sector has accounted for a rising share of global GDP. In the US, the share has risen to a full 19% of GDP. The OECD countries average 12%. In emerging markets, such as China and India, the share is only 5 and 4% respectively but is rising quickly, which indicates great potential.

Historically, equities in the healthcare sector have significantly outperformed the broader stock market. During the period January 1995 – October 2018, the MSCI World Healthcare Index returned 685% compared to 211% for the MSCI World Index (a broad world index for equities), measured in USD.

…with continued strong growth prospects

Two strong mega-trends indicate continued strong growth prospects for the healthcare sector: rising standards of living globally and an aging population. These trends also result in a large number of diseases, such as obesity and diabetes, especially in developing countries. In addition to this, emerging economies, China and India in particular, are increasingly investing in healthcare through state health insurance and by improving access to healthcare.

Diversified portfolio

The fund strives to diversify across geographies, companies and sub-sectors in order to mitigate risk.

Since most companies are listed in the US, the US market accounts for about two-thirds of the fund’s exposure. The remaining part is invested worldwide. The fund spreads its investments across the sub-sectors pharmaceuticals, biotechnology, medical technology and services and holds about one-third each in small, medium and large companies.

The hedge fund’s flexible investment mandate creates significantly greater opportunities compared with conventional equity funds. This is also the reason why the fund is not benchmarked against any stock index but instead aims to achieve a positive annual return, regardless of how the stock market develops.